STADA Places Second Tranche of Capital Increase
10/13/2003 . Ad hoc Release
Today, the executive board of STADA Arzneimittel AG adopted a resolution regarding the implementation of the second tranche of the capital increase resolved on 22 September 2003. After the settlement of the first tranche which was implemented as a capital increase with subscription rights for the shareholders at a ratio of 4:1, a second tranche of up to 1,869,171 shares of STADA Arzneimittel AG will be placed excluding the subscription rights of the shareholders.
The shares will be offered in a public offer in Germany and in a private placement in other member states of the EU, Switzerland and the United States of America (in reliance on Rule 144A of the US Securities Act 1933).
Deutsche Bank AG as Global Coordinator and Bookrunner will implement the placement by means of a so-called &qout;Accelerated Bookbuild Offering". Other Consortium Banks are DZ Bank (Co-Lead Manager), HSBC Trinkaus & Burkhardt and Merrill Lynch. Sal. Oppenheim will participate in the placement as Selling Group Member.
Up to 1,682,260 shares originate from the capital increase excluding the subscription rights of the shareholders. Further, the company granted an option (a so-called "Greenshoe") with respect to over-allotment of up to 186,911 shares to the Consortium Banks.
For more information, please contact:
STADA Arzneimittel AG
D-61118 Bad Vilbel
Tel.: +49 6101 603-113
Fax: +49 6101 603-506